Summit Therapeutics appoints Ankur Dhingra as CFO with $450k base salary

Summit Therapeutics Inc.

Ankur Dhingra named CFO effective May 31, 2022, replacing interim CFO Robert W. Duggan (who remains CEO).
Annual base salary of $450,000; eligible for performance bonus up to 50% of base.
Granted option to purchase 600,000 shares (10-year term, 4-year graded vesting, strike at grant-date close).
Dhingra previously CFO at CareDx and held finance roles at Agilent Technologies; also oversees IT and HR.
No written employment agreement; no family relationships or material transactions disclosed.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ankur Dhingra

Chief Financial Officer

SMMT · Summit Therapeutics Inc.

Effective: 2022-05-31
Filed: June 1, 2022, 7:59 PM ET

Effective on May 31, 2022, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) appointed Ankur Dhingra to serve as Chief Financial Officer and Principal Accounting Officer of the Company.

Role change (interim)

Robert W. Duggan

interim principal financial officer

SMMT · Summit Therapeutics Inc.

Effective: 2022-05-31
Successor: Ankur Dhingra
Filed: June 1, 2022, 7:59 PM ET

Mr. Dhingra will replace Robert W. Duggan, who was acting as the Company’s interim principal financial officer since the departure of Michael Donaldson as Chief Financial Officer on July 2, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ankur Dhingra was appointed as Chief Financial Officer at Summit Therapeutics Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Effective on May 31, 2022, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) appointed Ankur Dhingra to serve as Chief Financial Officer and Principal Accounting Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Robert W. Duggan changed role as interim principal financial officer at Summit Therapeutics Inc..

Role: interim principal financial officer

Exact text from the filing

Mr. Dhingra will replace Robert W. Duggan, who was acting as the Company’s interim principal financial officer since the departure of Michael Donaldson as Chief Financial Officer on July 2, 2021.

View on SEC.gov

Summit Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001599298-22-000051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.